Abstract
BACKGROUND: B7x is overexpressed in female reproductive system malignancies. The aim of this study was to evaluate the predictive value of B7x expression in the clinicopathological characteristics and prognosis of female reproductive system malignancies. METHODS: PubMed, Embase, Cochrane library, Web of Science, China National Knowledge Infrastructure, and Wanfang databases were searched for studies focused on the role of B7x expression in the clinicopathological features and prognosis of female breast cancer and malignant tumors of reproductive system, published up to April 2024. STATA 14.0 were used to perform the meta-analysis. RESULTS: A total of 36 eligible studies involving 2451 women with malignancy of the reproductive system were included in this meta-analysis. The results showed that in terms of clinicopathological features, B7x was closely related to lymph node status (odds ratio [OR] = 2.80, 95% confidence interval [CI] = 1.54-5.11, P = .001), tumor differentiation (OR = 2.95, 95% CI = 1.91-4.57, P < .001), and FIGO stage (OR = 3.88, 95% CI = 3.04-4.94, P < .001) of female reproductive system malignant tumor patients. In terms of prognosis: B7x expression is strongly associated with shorter PFS in female reproductive system malignancies (HR = 1.30, 95% CI = 1.17-1.45, P < .001). B7x may be a new target for immunotherapy and a biomarker for predicting poor prognosis in female malignant tumors of reproductive system. CONCLUSION: In summary, B7x is closely associated with clinicopathological features and poor prognosis of malignant tumors of the female reproductive system.